Revelation Biosciences, Inc. (NASDAQ:REVB) Forecasted to Earn Q3 2024 Earnings of ($1.59) Per Share

Revelation Biosciences, Inc. (NASDAQ:REVB) – Stock analysts at Roth Capital lowered their Q3 2024 EPS estimates for Revelation Biosciences in a research report issued on Monday, August 12th. Roth Capital analyst J. Aschoff now expects that the company will earn ($1.59) per share for the quarter, down from their previous estimate of ($1.44). The consensus estimate for Revelation Biosciences’ current full-year earnings is ($7.54) per share. Roth Capital also issued estimates for Revelation Biosciences’ Q4 2024 earnings at ($0.85) EPS, FY2024 earnings at ($8.60) EPS, FY2025 earnings at ($5.22) EPS, FY2026 earnings at ($5.41) EPS, FY2027 earnings at ($3.27) EPS and FY2028 earnings at $2.76 EPS.

Revelation Biosciences Stock Performance

REVB stock opened at $0.90 on Wednesday. The firm has a market cap of $1.46 million, a price-to-earnings ratio of -0.03 and a beta of 0.21. The firm has a 50-day simple moving average of $1.74 and a two-hundred day simple moving average of $2.38. Revelation Biosciences has a one year low of $0.88 and a one year high of $28.20.

Revelation Biosciences Company Profile

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.